OS Therapies Incorporated OSTX
Set alert
1.16 USD +0.01 +0.98%
As of Nov 3, 1:24 PM ET
1.16 Day range 1.22
1.12 52-week range 2.25
- YTD
- -17.05%
- 1 year
- -37.90%
- Open
- 1.16
- Prev close
- 1.15
- Mkt cap
- 54.53M
- Vol
- 240.94K
- Avg vol
- 599.30K
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.16
- High
- 1.22
- Forward P/E
- 2.57
- Beta
- 0.00
- Short ratio
- 1.22
- Inst. own
- 0.75%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.72
- 200-d avg
- 3.11
- 1y target
- 12.67
2Y chart
Events in this range
- Nov 26, 2024Rating: Maxim Group · — → Buy
Signals (105)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Nov 2, 2026 | 1 day ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 3 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
Newest 20 of 105.
Key statistics
- Market cap
- 80.28M
- Enterprise value
- 62.55M
- Trailing P/E
- 0.00
- Forward P/E
- 2.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.35
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 94.92K
- Total debt
- 16.70M
- Return on equity
- 0.00%
- Shares outstanding
- 21.24M
- Short % of float
- 0.00%
- 50-day average
- 2.72
- 200-day average
- 3.11
Analyst view
Price target (mean) 12.67 +990.7% upside
Now 1.16
- Target (low)
- 8.00
- Target (mean)
- 12.67
- Target (high)
- 21.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.14.
Financials — quick view
OSTX Revenue — quarterly 0
OSTX Net income — quarterly -8.63M
OSTX EPS — quarterly -0.20
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Maxim Group | init | — | Buy |
| Oct 3, 2024 | EF Hutton | main | Buy | Buy |
| Sep 16, 2024 | EF Hutton | main | Buy | Buy |
| Sep 3, 2024 | EF Hutton | init | — | Buy |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ostherapies.com
News
- OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
- Rubenstein Public Relations Named Agency of Record for OS Therapies
- OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma
- OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
- OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
- OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
- OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control
- OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
- OS Therapies Appoints Frank Knuettel II As CFO
- OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Your note
Sign in to keep a note on OSTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Millennium Management Llc | 0.28% | 60,435 | 228.44K | Sep 29, 2024 |
| CM Management, LLC | 0.24% | 50,000 | 189.00K | Sep 29, 2024 |
| Delta Investment Management, LLC | 0.09% | 18,081 | 68.35K | Sep 29, 2024 |
| HRT Financial LP | 0.08% | 17,576 | 66.44K | Sep 29, 2024 |
| Virtu Financial LLC | 0.05% | 10,045 | 37.97K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 3,806 | 14.39K | Sep 29, 2024 |